Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) have earned an average rating of “Buy” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target […]
Adicet Bio (NASDAQ:ACET – Get Rating) had its price target trimmed by JMP Securities from $30.00 to $21.00 in a research report sent to investors on Thursday, The Fly reports. The firm currently has a market outperform rating on the stock. A number of other analysts also recently issued reports on ACET. HC Wainwright reissued […]
Adicet Bio (NASDAQ:ACET – Get Rating) released its quarterly earnings results on Tuesday. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.05), MarketWatch Earnings reports. Shares of NASDAQ:ACET traded up $0.30 during midday trading on Thursday, reaching $16.24. The company’s stock had a trading volume of […]
MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on February 28, 2022 (the “Grant Date”) under Adicet’s 2022 Inducement Plan as a mater...
04.03.2022 - Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on February 28, 2022 (the “Grant Date”) under Adicet’s 2022 ...